Loading people...
Eric Aguiar is a Partner at Aisling Capital based in New York, New York, where he focuses on life sciences and healthcare venture capital investments. Before joining Aisling Capital, he served as a Partner at Thomas, McNerney & Partners, a Managing Director at HealthCare Ventures, and the Chief Executive Officer of the gene therapy company Genovo. Aguiar has directed investments across the biotechnology sector and held long-term board positions, including serving as a director for BridgeBio Pharma since 2015 and previously sitting on the board of medical genetics company Invitae. He earned his medical degree with honors from Harvard Medical School and received a bachelor of arts degree from Cornell University. As a former physician, his current focus remains on leveraging his clinical expertise to guide biopharmaceutical startups through drug development, regulatory approvals, and commercialization.
Eric Aguiar stands as a key Partner at Aisling Capital, a renowned venture capital firm dedicated to the life sciences sector. With a deep understanding of the intricate landscape of healthcare innovation, Mr. Aguiar is instrumental in shaping Aisling Capital's investment strategy and portfolio. His work primarily involves sourcing, evaluating, and managing investments in groundbreaking companies within biotechnology, pharmaceuticals, and medical devices.
At Aisling Capital, Eric Aguiar leverages his extensive industry knowledge to identify promising opportunities that have the potential to significantly impact patient care and global health. He is actively involved in guiding portfolio companies through various stages of development, from early-stage growth to late-stage expansion, providing strategic oversight and operational support. His commitment to fostering innovation is evident in his approach to partnering with visionary entrepreneurs and scientific leaders.
Before joining Aisling Capital, Mr. Aguiar built an impressive career in healthcare investment banking. He served as a Managing Director in the Healthcare Investment Banking Group at Merrill Lynch, where he advised numerous companies on mergers, acquisitions, and capital market transactions. Prior to his tenure at Merrill Lynch, he held a Senior Managing Director position in the Healthcare Investment Banking Group at Bear Stearns. His earlier career also included significant roles at SG Cowen and Lehman Brothers, further solidifying his expertise in financial advisory within the healthcare industry. This robust background in investment banking provides him with a unique perspective on valuation, deal structuring, and market dynamics, which he applies effectively in his venture capital role.
Eric Aguiar's educational foundation includes a Master of Business Administration from Columbia Business School and a Bachelor of Arts from Dartmouth College. This strong academic background, combined with decades of practical experience, underpins his analytical rigor and strategic acumen. His contributions to Aisling Capital reinforce the firm's reputation as a leader in life sciences venture capital, continually seeking to invest in and develop the next generation of healthcare breakthroughs. Through his leadership, Aisling Capital continues to support companies that are at the forefront of medical innovation, addressing unmet medical needs and improving quality of life worldwide.
Eric Aguiar is a Partner at Aisling Capital, a leading venture capital firm specializing in life sciences investments. He is known for his expertise in biotechnology, pharmaceuticals, and medical devices.
Eric Aguiar primarily invests in companies within the life sciences sector, focusing on biotechnology, pharmaceuticals, and medical devices. He seeks innovative companies with the potential to advance healthcare.
Eric Aguiar works as a Partner at Aisling Capital, a prominent venture capital firm based in New York, dedicated to investing in the life sciences industry.
